ASCO胃肠道会议进展-张俊.pptxVIP免费

张俊上海交通大学医学院附属瑞金医院外科、肿瘤放化疗科上海消化外科研究所ASCO-GI2022(18-20Jan2022,SF)ASCO胃肠道会议进展第一页，共三十九页。Highlightsof2022ASCOGI结直肠癌辅助化疗Abstract#362：AVANT(XELOX+BVZVSFOLFOX+BVZVSFOLFOXalone)Abstract#363：NO147(FOLFIRIR±西妥昔单抗〕一线化疗Abstract#365：NORDICVII〔FLOX+西妥昔单抗一线治疗mCRC〕打打停停：mCRC标准治疗后以贝伐珠单抗＋卡培他滨维持治疗平安有效第二页，共三十九页。AVANT：研究设计高危II期/III期结肠癌患者行手术治疗(N=3451)FOLFOX4观察随访FOLFOX4+贝伐单抗贝伐单抗单药随访XELOX+贝伐单抗贝伐单抗单药随访Bev5mg/kgq2wBev7.5mg/kgq3wBev7.5mg/kgq3wBev7.5mg/kgq3w24周24周DeGramontA,etal.2022ASCOGIAbstract362.第三页，共三十九页。研究执行情况和终点指标330centers,34countries,8regions(stratified)3451patientsrandomizedbetween20December2004and08June2007-2867patientswithStageIIIdiseasePrimaryendpoints(StageIIIpatientsonly):DFS:FOLFOX4+bevacizumabvs.FOLFOX4DFS:XELOX+bevacizumabvs.FOLFOX4Secondaryendpoints:OSSafetyNon-inferiorityofDFSandOSforFOLFOX4+bevacizumabvs.XELOX+bevacizumab(ifco-primaryendpointsmet)第四页，共三十九页。DFS(ITTStageIII)Datacut-offdate:30June2022(3-yearminimumfollow-up)FOLFOX(N=955)FOLFOX4+Bev(N=960)XELOX+Bev(N=952)HR(95%CI)1.17(0.98,1.39)1.07(0.90,1.28)955960952890921900823868865779791784740728722708695688451436415FOLFOX4FOLFOX4+BevXELOX+BevNumberatrisk609586580282280268FOLFOX4FOLFOX4+BevXELOX+BevEvent-freerate0.00.10.20.30.40.50.60.70.80.91.06183036424801224Time(months)54606672121123110010323328000第五页，共三十九页。AVANT结果小结DFS〔至少3年随访期〕HRFOLFOX+BVZ1.17(0.98,1.39),(73%3yDFS)HRXELOX+BVZ1.07(0.9,1.28),(75%3yDFS)组间无差异1年的DFSHR结果与NSABP-08类似，但1年后消失是否rebound因素？两组的复发部位类似〔BVZ组并未更差〕复发后的生存时间差异不大第六页，共三十九页。SiteofRecurrence(ITTStageIII)FOLFOX4(N=955)n(%)FOLFOX4+Bev(N=960)n(%)XELOX+Bev(N=952)n(%)Patientswithtumorrecurrence*219(23)252(26)223(23)Localrecurrence39(4)42(4)47(5)Regionallymphnodes19(2)22(2)21(2)Distantlymph...